Investor News Oliver Maier Head of Investor Relations Fresenius Medical Care Else-Kr ner-Stra e 1 61352 Bad Homburg Germany T +49 6172 609-2601 F +49 6172 609-2301 oliver.maier@fmc-ag.com www.fmc-ag.com

Fresenius Medical Care Reports Excellent First Quarter 2012 Results

And Confirms Guidance For Full Year 2012

1st Quarter 2012 Summary:

Bad Homburg, Germany - Fresenius

Medical Care AG & Co. KGaA (the "company" or "Fresenius Medical Care";

Frankfurt Stock Exchange: FME / New York Stock Exchange: FMS), the world's largest provider of dialysis products and services,

today announced its results for the first quarter of 2012.

* Attributable to shareholders of

Fresenius Medical Care AG & Co. KGaA

Net revenue for the first quarter of 2012

increased by 9% to $3,249 million

(+10% at constant currency) compared to the first quarter of 2011. Organic revenue growth worldwide was 3%. Dialysis services

revenue grew by 11% to $2,478 million (+12% at constant currency) and dialysis product revenue increased by 3% to $771 million

(+5% at constant currency).

North America revenue for

the first quarter of 2012 increased by 9% to $2,105 million. Dialysis services revenue grew by

11% to $1,918 million with a same market growth of 3%. Average revenue per treatment for U.S. clinics increased to $353 in the

first quarter of 2012 compared to $348 for the corresponding quarter in 2011. Dialysis product revenue decreased

by 4% to $187 million mainly as a result of lower pricing of renal pharmaceuticals.

International revenue increased by 8% to $1,136 million (+

12% at constant currency). Organic revenue growth was 6%. Dialysis services revenue increased by 11% to $560 million (+16%

at constant currency). Dialysis product revenue increased by 4% to $576 million and increased by 8% at constant currency,

mainly driven by higher sales of dialysis machines.

Operating income (EBIT) for the first quarter

of 2012 increased by 13% to $503 million compared to $445 million in the first quarter of 2011. This resulted in an operating margin

of 15.5% for the first quarter of 2012 compared to 14.9% for the corresponding quarter in 2011.

In North America, the operating margin increased from 16.2% to

16.5%. The increase in Medicare rates and the growth of our expanded services contributed favorably to this development. Average costs per treatment for U.S. clinics decreased to $286 in the first quarter of 2012 compared to

$288 for the corresponding quarter in 2011.

In the International segment, the operating margin

increased from 16.2% to 17.2%, mainly due to favorable exchange rate effects.

Net interest expense for the first quarter of 2012 was

$99 million, compared to $72 million in the first quarter of 2011. This development was mainly attributable to

the higher level of financial debt as a result of the issuance of various tranches of senior notes over the course of 2011 and

Net income attributable to shareholders of Fresenius Medical

Care AG & Co. KGaA for the first quarter of 2012 was $370 million, an increase of 68% compared to the corresponding

quarter of 2011. This includes a non-taxable investment gain of $127 million related to the acquisition of Liberty Dialysis Holdings,

Inc., including its 51% stake in Renal Advantage Partners, LLC (RAI). The gain is a result of measuring the 49% equity interest

in RAI held by the company at its fair value at the time of the Liberty acquisition and is subject to the finalization of the Liberty

purchase accounting. Excluding this investment gain net income attributable to shareholders of Fresenius Medical Care AG &

Co. KGaA increased by 10% to $244 million.

Income tax expense was $137 million for the first quarter

of 2012 compared to $124 million in the first quarter of 2011. The effective tax rate decreased to 25.8% from 33.3%

driven by the non-taxable investment gain. Excluding the investment gain the effective tax rate was 33.9%.

Earnings per ordinary share (EPS) for the first quarter 2012

was $1.22 and $0.80 if excluding the investment gain. This represents an increase compared to the first quarter of 2011 of 67%

and 10%, respectively. The weighted average number of shares outstanding for the first quarter of 2012 was approximately 304.2 million

shares, compared to 302.3 million shares for the first quarter of 2011.

The increase in shares outstanding resulted from stock option exercises in the past 12 months.

In the first quarter of 2012, the company generated $481 million

in cash from operations, an increase of 174% compared to the corresponding figure last year and representing approximately

14.8% of revenue. The cash flow generation was supported by a favorable development of DSO and inventory levels as well as lower

income tax payments.

A total of $122 million was spent for capital expenditures,

net of disposals. Free cash flow before acquisitions was $359 million compared to $62 million in the first quarter of 2011.

A total of $1,526 million in cash was spent for acquisitions and investments, net of divestitures. Free cash

flow after acquisitions and divestitures was minus $1,167 million, compared to minus $277 million in the first quarter of 2011.

Please refer to the attachments for a complete

overview on the first quarter of 2012 and the reconciliation of non-GAAP financial measures included in this release to the most

comparable GAAP financial measures.

Patients - Clinics - Treatments

As of March 31, 2012, Fresenius Medical Care treated 253,041 patients

worldwide, which represents a 17% increase compared to the previous year's figure. North America provided dialysis treatments

for 161,656 patients, an increase of 17%. Including 21 clinics managed by Fresenius Medical Care North America, the number

of patients in North America was 163,261. The International segment provided dialysis treatment to 91,385 patients, an increase

of 16% over the prior year's figure.

As of March 31, 2012, the company operated a total of 3,119 clinics

worldwide, which represents a 13% increase compared to the previous year's figure. The number of clinics is comprised of

2,053 clinics in North America (2,074 including managed clinics), and 1,066 clinics in the International segment, representing

an increase of 13% and 13%, respectively.

During the first quarter of 2012, Fresenius Medical Care delivered

approximately 9.21 million dialysis treatments worldwide. This represents an increase of 13%, compared to last year's

figure. North America accounted for 5.75 million treatments, an increase of 10%. The International segment delivered 3.47 million

treatments, an increase of 18%.

As of March 31, 2012, Fresenius Medical Care had 82,979 employees

(full-time equivalents) worldwide, compared to 79,159 employees at the end of 2011. This increase of more than 3,800 employees

is due to overall growth in the company's business and acquisitions including Liberty Dialysis Holdings, Inc.

The ratio of debt to Earnings before interest, taxes, depreciation

and amortization (EBITDA) increased from 2.55 at the end of the first quarter of 2011 to 2.96 at the end of the first quarter of

2012. The debt/EBITDA ratio at the end of 2011 was 2.69.

In February Standard & Poor's Ratings Services upgraded

the company's corporate credit to BB+' from BB'. The agency also raised the ratings of Fresenius

Medical Care's various unsecured senior notes to BB+' from BB'. The rating of BBB-'

on Fresenius Medical Care's senior secured credit facilities was affirmed. A stable outlook has been assigned to all ratings.

Moody's rates the company's corporate credit as Ba1' with a stable' outlook, and Fitch rates the

company's corporate credit as BB+' with a stable' outlook. For further information on Fresenius

Medical Care's credit ratings, maturity profiles and credit instruments, please visit our website at www.fmc-ag.com / Investor

Relations / Credit Relations.

Announcement of Management Board Change

On March 9, 2012, Fresenius Medical Care announced a change in

the Management Board. Rice Powell will succeed Dr. Ben J. Lipps as CEO of Fresenius Medical Care AG & Co. KGaA and Chairman

of the Management Board, effective January 1, 2013. The appointment of Rice Powell is part of the company's succession plan

to ensure a smooth transition of leadership. Ben Lipps was appointed Chief Executive Officer and Chairman of the Management Board

in 1999. In recognition of his extraordinary achievements and unique expertise Dr. Ben J. Lipps has been appointed Honorary

Chairman of the supervisory boards of Fresenius Medical Care AG & Co. KGaA and the Fresenius Medical Care Management AG, effective

Closing of the acquisition of Liberty Dialysis Holdings

Fresenius Medical Care North America has closed the acquisition

of Liberty Dialysis Holdings, Inc., the holding company of Liberty Dialysis and Renal Advantage effective February 28, 2012. The